SEC Form 10-Q Summary
Filing entity: Pono Capital Two, Inc., not SBC Medical Group Holdings Inc. The filing covers the quarterly period ended June 30, 2022 and was filed September 9, 2022.
Business Context and Reporting Period
Pono Capital Two was a newly formed Delaware blank-check company incorporated on March 11, 2022. It had not commenced operations or selected a business-combination target as of June 30, 2022. Activity during the period related primarily to formation and preparation for its initial public offering. The financial statements are unaudited and cover the three months ended June 30, 2022 and the period from inception through June 30, 2022.
Financial Condition and Results
- Revenue: None. The company does not expect operating revenue until after completing a business combination.
- Net loss: $1,281 for the quarter and $1,620 from inception through June 30, 2022.
- Expenses: Quarterly operating costs were $1,208 and formation costs were $73. Cumulative operating costs were $1,208 and formation costs were $412.
- Cash flow: Net cash used in operating activities was $5,764 from inception. Net cash provided by financing activities was $185,193, resulting in ending cash of $179,429.
- Balance sheet: Total assets were $362,107, including $179,429 of cash, $4,144 of prepaid expenses and $178,534 of deferred offering costs.
- Liabilities: Total liabilities were $338,727, consisting primarily of a $300,000 non-interest-bearing promissory note payable to the Sponsor and $38,727 of accrued offering costs.
- Equity: Stockholders’ equity was $23,380, including an accumulated deficit of $1,620.
- Margins and debt metrics: Operating margins are not meaningful because the company had no revenue. The filing does not provide a conventional debt-to-equity or liquidity ratio; the principal debt was the related-party promissory note.
Material Changes and Subsequent Events
- After the reporting date, on August 9, 2022, the company completed an initial public offering of 11,500,000 units, generating gross proceeds of $115.0 million. The underwriters exercised the over-allotment option in full.
- Also on August 9, 2022, the Sponsor purchased 634,375 placement units for gross proceeds of $6.34 million.
- Following the offering, $117.875 million was deposited into a trust account, generally to fund a future business combination or redemptions.
- The $300,000 related-party promissory note was repaid at the IPO closing.
- Total offering transaction costs were reported at $6.64 million, including $4.025 million of deferred underwriting commissions payable only if a business combination is completed.
- The underwriters’ full exercise of the over-allotment option eliminated forfeiture provisions applicable to up to 375,000 Founder Shares.
Guidance, Outlook, Risks and Unusual Items
- Management had not identified a target or begun substantive discussions regarding a business combination as of the filing date.
- The company must complete a business combination by May 9, 2023, subject to possible extensions of up to February 9, 2024 if specified conditions are satisfied. Failure to complete a transaction would require liquidation, redemption of public shares and dissolution.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern if a business combination is not completed by the mandatory liquidation date.
- Public stockholders may redeem their shares in connection with a business combination or liquidation. The company generally must maintain at least $5,000,001 of net tangible assets after redemptions.
- The Sponsor may provide up to $1.5 million of working-capital loans, and extension financing may be available if the combination period is extended. Such financing could be convertible into additional units.
- The company identified potential adverse effects from the COVID-19 pandemic and the Russia-Ukraine conflict, including difficulty completing a transaction or obtaining financing.
- The Sponsor agreed to indemnify the trust account in certain circumstances if third-party claims reduce its value below $10.25 per public share, subject to stated exceptions.
- No legal proceedings, defaults, unregistered equity sales or material changes to previously disclosed risk factors were reported.
- Management concluded that disclosure controls and procedures were effective as of June 30, 2022, with no material changes in internal control over financial reporting.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for Pono Capital Two, Inc., not SBC Medical Group Holdings Inc.
- Confirm the post-quarter-end IPO, private placement, trust-account balance and repayment of the related-party note in subsequent filings.
- Track whether a business-combination target is identified and whether the transaction satisfies the 80% fair-market-value requirement.
- Monitor public-share redemptions, minimum net tangible assets and any extensions of the combination deadline.
- Review the deferred underwriting commissions, Sponsor loans, potential dilution from Founder Shares and warrants, and liquidation provisions.
- Assess the going-concern risk if no business combination is completed by the applicable deadline.